News
Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
Cephalon, Inc.announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients...
News
Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.
Bristol-Myers Squibb Company announced that it has completed its previously announced acquisition of ZymoGenetics, Inc.. As a result of the transaction, ZymoGenetics has become a wholly-owned subsidiary of Bristol-Myers Squibb. Bristol-Myers Squibb initiated on September 10,...
News
BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX for Treatment of Peyronie’s Disease
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first subject in the global Phase 3 program of XIAFLEX® (collagenase clostridium histolyticum) for the treatment...
News
AstraZeneca and PoZEN received approval for VIMOVO in Europe
AstraZeneca and POZEN Inc. today announced that VIMOVO (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets has cleared an important regulatory milestone by receiving positive agreement for approval in 23 countries across the European Union (EU). This follows all 22...
News
Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)
Bexion Pharmaceuticals announced that it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The grant entitled “SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme” was awarded September 28, 2010 and...
News
Abbott Named One of the “Top Employers” in the Biotech and Pharmaceutical Industry by Science Magazine
Abbott Park, Illinois was named one of the top 20 employers in Science magazine's 2010 Top Biopharma Employers survey. The annual survey seeks to identify the companies with the best reputations as employers. According to the survey, Abbott's top...
News
Lupin Announces Final FDA Approval of Generic Hyzaar® and Cozaar
Pharma Major, Lupin Limited announced that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has been granted final approval for the company's generic versions of Merck's antihypertensive agents *Hyzaar® (hydrochlorothiazide; losartan potassium) and *Cozaar® (losartan potassium) by the U.S. Food...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read